Physician

Alan Bulbin, M.D.

According to 2025 Medicare claims, Alan Bulbin, M.D. (NPI: 1053360628) practices infectious disease in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Nassau, NY. This provider's primary affiliated billing organization is CHS PHYSICIAN PARTNERS, P.C (NPI: 1164585725; TIN: 113613997) and primary practice location at 11576-1347. Bulbin is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Bulbin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 868 traditional Medicare patients, billed 1,949 HCPCS/CPT codes, and received $186,813 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 788 prescription claims across 109 beneficiaries totaling $1,154,743 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). Open Payments data shows 113 records totaling $22,677. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $579,612 to $1,154,743. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,078	2,678	$269,602
2016	1,043	2,519	$228,701
2017	1,006	2,238	$182,251
2018	985	2,270	$190,945
2019	1,011	2,260	$200,932
2020	1,075	2,893	$257,894
2021	1,047	2,686	$243,652
2022	1,016	3,135	$273,900
2023	917	2,466	$234,425
2024	868	1,949	$186,813

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	48	635	$579,612
2016	46	564	$575,933
2017	40	554	$553,403
2018	41	647	$686,482
2019	56	674	$744,568
2020	63	698	$756,329
2021	79	707	$840,755
2022	80	741	$963,263
2023	85	743	$1,160,019
2024	109	788	$1,154,743

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	301	309	$155
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	85	128	$116
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	93	99	$110
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	51	64	$83
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	554	1,202	$72

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	124	3,720	$506,431
Juluca	Dolutegravir/Rilpivirine	60	1,800	$212,180
Dovato	Dolutegravir Sodium/Lamivudine	52	1,727	$173,285
Prezcobix	Darunavir/Cobicistat	23	690	$61,681
Tivicay	Dolutegravir Sodium	23	690	$58,505

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	113	$22,677	Cumberland Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Bulbin, M.D.?

Tedicare shows public-source Medicare data for Alan Bulbin, M.D. (NPI 1053360628), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Bulbin, M.D. have ACO affiliation data?

Alan Bulbin, M.D. is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Alan Bulbin, M.D.?

Alan Bulbin, M.D. is linked to CHS PHYSICIAN PARTNERS, P.C (billing NPI 1164585725) in the available physician profile data.

Does Alan Bulbin, M.D. have Open Payments data?

Alan Bulbin, M.D. has 113 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.